Company intelligence / Profile preview
Shanghai Saiyuan Biotechnology
Shanghai, Shanghai, Chinasaiyuanbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Saiyuan Biotechnology is a clinical-stage biopharmaceutical company focused on developing next-generation cell therapies for solid tumors. Based in Shanghai, the company utilizes its proprietary CAR-T and TCR-T technology platforms to address the limitations of current immunotherapies in treating complex malignancies. Its lead program, SY-001, is a GPC3-targeted CAR-T therapy currently in Phase 1 clinical trials for advanced liver cancer. Saiyuan's pipeline also includes candidates targeting Claudin 18.2 and other validated tumor antigens, supported by an integrated R&D and manufacturing infrastructure.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Shanghai Saiyuan Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Saiyuan Biotechnology.